Your browser doesn't support javascript.
loading
Safety assessment of RhD-positive red cell transfusion in RhD-negative liver-transplant recipients: Single-centre report from India.
Tiwari, Aseem Kumar; Arora, Dinesh; Aggarwal, Geet; Dara, Ravi C; Bhardwaj, Gunjan; Sharma, Jyoti; Vohra, Vijay; Soin, Arvinder Singh.
Afiliação
  • Tiwari AK; Department of Transfusion Medicine, Medanta-The Medicity, Gurugram, Haryana, India.
  • Arora D; Department of Transfusion Medicine, Medanta-The Medicity, Gurugram, Haryana, India.
  • Aggarwal G; Department of Transfusion Medicine, Medanta-The Medicity, Gurugram, Haryana, India.
  • Dara RC; Department of Transfusion Medicine, Manipal Hospital, Jaipur, Rajasthan, India.
  • Bhardwaj G; Department of Transfusion Medicine, Medanta-The Medicity, Gurugram, Haryana, India.
  • Sharma J; Department of Transfusion Medicine, Medanta-The Medicity, Gurugram, Haryana, India.
  • Vohra V; Department of Liver Transplant Anesthesia, Medanta-The Medicity, Gurugram, Haryana, India.
  • Soin AS; Department of Institute of Liver Transplantation & Regenerative Medicine, Medanta-The Medicity, Gurugram, Haryana, India.
Indian J Med Res ; 152(6): 662-666, 2020 Dec.
Article em En | MEDLINE | ID: mdl-34145107
ABSTRACT
BACKGROUND &

OBJECTIVES:

The number of blood components required during a liver-transplant surgery is significant. It is challenging for blood transfusion services to provide the required RhD-negative red blood cells (RBCs) for recipients during the peri-operative period. This retrospective study presents safety data of transfusing RhD-positive RBCs in RhD-negative living donor liver-transplant (LDLT) recipients during the peri-operative period with six-month follow up for risk of developing alloantibodies.

METHODS:

All RhD-negative patients who underwent LDLT and were transfused ABO-compatible but RhD-positive RBC units between January 2012 and May 2018 were included in the study. Twenty one RhD-negative patients who received a total of 167 RhD-positive RBCs peri-operatively were chosen for alloantibody screening. All the patients were started on triple immunosuppression drugs as per the standard hospital protocol. Blood grouping, cross-match and antibody screening were done by column agglutination technique.

RESULTS:

Post-transplant antibody screen (weekly for 12 wk) was negative, and none of the patients developed anti-D alloantibodies till their last follow up (mean 21 months). INTERPRETATION &

CONCLUSIONS:

Our observations suggest that it may be safe to use RhD-positive RBCs peri-operatively in RhD-negative LDLT recipients with low risk of alloimmunization.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Indian J Med Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado Tipo de estudo: Observational_studies Limite: Humans País/Região como assunto: Asia Idioma: En Revista: Indian J Med Res Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia